Chinese Expert Consensus on the Multidisciplinary Diagnosis and Management of Hepatocellular Carcinoma with Extrahepatic Metastases（2026 Edition）_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

 WU Hong ,  YANG Jiayin ,  XIE Kunlin

Chinese Society of Liver Cancer, China Anti-Cancer Association;

Corresponding?author：

WU Hong, Email: wuhong@scu.edu.cn; YANG Jiayin, Email: doctoryjy@scu.edu.cn; XIE Kunlin, Email: xiekun@scu.edu.cn

Keywords：

hepatocellular carcinoma; extrahepatic metastasis; multidisciplinary management; systemic therapy; local treatment; organ-specific treatment

DOI：

10.7507/1007-9424.202607011

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Extrahepatic metastasis in hepatocellular carcinoma indicates that the disease has progressed from a liver-confined lesion to an advanced systemic stage, representing an important clinical condition that influences therapeutic decision-making and patient prognosis. These patients are often characterized by a complex background of chronic liver disease, impaired hepatic functional reserve, variable intrahepatic primary tumor burden, and substantial heterogeneity in the site, extent, and burden of extrahepatic metastases, resulting in marked variability in disease status and therapeutic needs and substantial complexity in clinical decision-making. In recent years, with the rapid development of systemic therapies for advanced hepatocellular carcinoma and the continuous refinement of local and locoregional approaches, including surgery, interventional therapy, ablation, and radiotherapy, the treatment paradigm for this population has gradually shifted from single-discipline decision-making to comprehensive multidisciplinary management. In clinical practice, the management of patients with hepatocellular carcinoma and extrahepatic metastases requires not only evaluation of intrahepatic tumor status, hepatic functional reserve, and the underlying liver disease, but also assessment of the location, extent, symptom burden, and risk of organ dysfunction related to extrahepatic lesions. These factors should be integrated with the patient’s general condition and tolerance to subsequent treatment in order to formulate a stage-specific and goal-directed management strategy. The Chinese Expert Consensus on the Multidisciplinary Diagnosis and Management of Hepatocellular Carcinoma with Extrahepatic Metastases（2026 Edition) systematically addresses key issues including multidisciplinary collaborative assessment and decision-making pathways, imaging evaluation, systemic therapy, and the integration of local treatment. It also provides organ-specific recommendations based on the clinical characteristics of metastases involving the lung, bone, lymph nodes, adrenal glands, peritoneum, and brain, with the aim of providing a reference for standardized multidisciplinary management of patients with hepatocellular carcinoma and extrahepatic metastases.

Citation： WU Hong, YANG Jiayin, XIE Kunlin. Chinese Expert Consensus on the Multidisciplinary Diagnosis and Management of Hepatocellular Carcinoma with Extrahepatic Metastases（2026 Edition）. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2026, 33(9): 1161-1184. doi: 10.7507/1007-9424.202607011 Copy

1.	Han B, Zheng R, Zeng H, et al. Cancer incidence and mortality in China, 2022 [J]. J Natl Cancer Cent, 2024, 4(1): 47-53.
2.	Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. CA Cancer J Clin, 2024, 74(3): 229-263.
3.	Sung H, Filho AM, Laversanne M, et al. Global cancer statistics 2024: GLOBOCAN estimates of incidence and mortality worldwide for 34 cancers in 186 countries [J/OL]. CA Cancer J Clin, 2026, 76(4): e70090. doi: 10.3322/caac.70090.
4.	李響, 李恒希, 鄭榮壽, 等. 2024全球癌癥統計數據解讀: 中國與全球對比 [J]. 中國普外基礎與臨床雜志, 2026, 33(8): 1009-1017.
5.	Wen B, Te L, Bai C, et al. Relative contribution of hepatitis B and C viruses in primary liver cancer in China: a systematic review and meta-analysis [J/OL]. J Infect, 2024, 89(6): 106298. doi: 10.1016/j.jinf.2024.106298.
6.	Li Q, Ding C, Cao M, et al. Global epidemiology of liver cancer 2022: an emphasis on geographic disparities [J]. Chin Med J (Engl), 2024, 137(19): 2334-2342.
7.	Amin MB, Greene FL, Edge SB, et al. The Eighth Edition AJCC Cancer Staging Manual: continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging [J]. CA Cancer J Clin, 2017, 67(2): 93-99.
8.	中華人民共和國國家衛生健康委員會醫政司. 原發性肝癌診療指南 (2024年版) [J]. 中國普通外科雜志, 2024, 33(4): 475-530.
9.	Reig M, Sanduzzi-Zamparelli M, Forner A, et al. BCLC strategy for prognosis prediction and treatment recommendations: the 2026 update [J]. J Hepatol, 2026, 84(3): 631-654.
10.	Uka K, Aikata H, Takaki S, et al. Clinical features and prognosis of patients with extrahepatic metastases from hepatocellular carcinoma [J]. World J Gastroenterol, 2007, 13(3): 414-420.
11.	Uchino K, Tateishi R, Shiina S, et al. Hepatocellular carcinoma with extrahepatic metastasis: clinical features and prognostic factors [J]. Cancer, 2011, 117(19): 4475-4483.
12.	廣東省抗癌協會肝癌專業委員會, 中山大學腫瘤防治中心肝膽科. 肝癌多學科綜合治療團隊建立—廣東專家共識 (1) [J]. 中國實用外科雜志, 2014, 34(8): 732-734.
13.	中國抗癌協會肝癌專業委員會. 中國肝癌多學科綜合治療專家共識 [J]. 肝癌電子雜志, 2020, 7(4): 2-8.
14.	中國抗癌協會肝癌專業委員會. 中國肝癌多學科綜合治療專家共識 (2025年版) [J]. 臨床肝膽病雜志, 2025, 41(7): 1279-1286.
15.	中共中央, 國務院. 中共中央國務院印發《“健康中國2030”規劃綱要》[EB/OL]. (2016-10-25) [2026-09-02]. https://www.nhc.gov.cn/guihuaxxs/c100132/201610/cef9821abcfc4544bb27e2bc533bd7cf.shtml.
16.	中華人民共和國國家衛生健康委員會醫政司. 原發性肝癌診療指南 (2026年版) [J]. 中國普外基礎與臨床雜志, 2026, 33(4): 425-485.
17.	Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations [J]. BMJ, 2008, 336(7650): 924-926.
18.	Gattrell WT, Logullo P, van Zuuren EJ, et al. ACCORD (ACcurate COnsensus Reporting Document): a reporting guideline for consensus methods in biomedicine developed via a modified Delphi [J/OL]. PLoS Med, 2024, 21(1): e1004326. doi: 10.1371/journal.pmed.1004326.
19.	國家癌癥中心. 中國肝癌規范診療質量控制指標 (2022版) [J]. 肝癌電子雜志, 2022, 9(4): 1-11.
20.	Cammarota A, Zanuso V, Pressiani T, et al. Assessment and monitoring of response to systemic treatment in advanced hepatocellular carcinoma: current insights [J]. J Hepatocell Carcinoma, 2022, 9: 1011-1027.
21.	Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma [J]. N Engl J Med, 2020, 382(20): 1894-1905.
22.	Abou-Alfa GK, Lau G, Kudo M, et al. Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma [J/OL]. NEJM Evid, 2022, 1(8): EVIDoa2100070. doi: 10.1056/EVIDoa2100070.
23.	Liou TC, Shih SC, Kao CR, et al. Pulmonary metastasis of hepatocellular carcinoma associated with transarterial chemoembolization [J]. J Hepatol, 1995, 23(5): 563-568.
24.	MacMahon H, Naidich DP, Goo JM, et al. Guidelines for management of incidental pulmonary nodules detected on CT images: from the Fleischner Society 2017 [J]. Radiology, 2017, 284(1): 228-243.
25.	Expert Panel on Gastrointestinal Imaging; Smith EN, Bashir MR, et al. ACR appropriateness criteria^? staging and follow-up of primary liver cancer [J]. J Am Coll Radiol, 2025, 22(11S): S699-S712.
26.	Lee JE, Jang JY, Jeong SW, et al. Diagnostic value for extrahepatic metastases of hepatocellular carcinoma in positron emission tomography/computed tomography scan [J]. World J Gastroenterol, 2012, 18(23): 2979-2987.
27.	?ukaszewski B, Nazar J, Goch M, et al. Diagnostic methods for detection of bone metastases [J]. Contemp Oncol (Pozn), 2017, 21(2): 98-103.
28.	Zhou J, Sun H, Wang Z, et al. China Liver Cancer Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2024 Edition) [J]. Liver Cancer, 2025, 14(6): 779-835.
29.	Longo V, Brunetti O, D’Oronzo S, et al. Bone metastases in hepatocellular carcinoma: an emerging issue [J]. Cancer Metastasis Rev, 2014, 33(1): 333-342.
30.	Costa F, Restelli F, Innocenti N, et al. Incidence, epidemiology, radiology, and classification of metastatic spine tumors: WFNS Spine Committee recommendations [J/OL]. Neurosurg Rev, 2024, 47(1): 853. doi: 10.1007/s10143-024-03095-4. doi: 10.1007/s10143-024-03095-4.
31.	Lin CY, Chen JH, Liang JA, et al. ¹⁸F-FDG PET or PET/CT for detecting extrahepatic metastases or recurrent hepatocellular carcinoma: a systematic review and meta-analysis [J]. Eur J Radiol, 2012, 81(9): 2417-2422.
32.	Jiang XB, Ke C, Zhang GH, et al. Brain metastases from hepatocellular carcinoma: clinical features and prognostic factors [J/OL]. BMC Cancer, 2012, 12: 49. doi: 10.1186/1471-2407-12-49. doi: 10.1186/1471-2407-12-49.
33.	Enrique GV, Irving SR, Ricardo BI, et al. Diagnosis and management of brain metastases: an updated review from a radiation oncology perspective [J/OL]. J Cancer Metastasis Treat, 2019, 5: 54. doi: 10.20517/2394-4722.2019.20. doi: 10.20517/2394-4722.2019.20.
34.	Ng PR, Choi BD, Aghi MK, et al. Surgical advances in the management of brain metastases [J]. Neurooncol Adv, 2021, 3(Suppl 5): v4-v15.
35.	Katyal S, Oliver JH 3rd, Peterson MS, et al. Extrahepatic metastases of hepatocellular carcinoma [J]. Radiology, 2000, 216(3): 698-703.
36.	Natsuizaka M, Omura T, Akaike T, et al. Clinical features of hepatocellular carcinoma with extrahepatic metastases [J]. J Gastroenterol Hepatol, 2005, 20(11): 1781-1787.
37.	Okuda K, Arakawa M, Kubo Y, et al. Right-sided pedunculated hepatocellular carcinoma: a form of adrenal metastasis [J]. Hepatology, 1998, 27(1): 81-85.
38.	Da Fonseca LG, Leonardi PC, Hashizume PH, et al. A multidisciplinary approach to peritoneal metastasis from hepatocellular carcinoma: clinical features, management and outcomes [J]. Clin Exp Hepatol, 2022, 8(1): 42-48.
39.	Lin CC, Liang HP, Lee HS, et al. Clinical manifestations and survival of hepatocellular carcinoma patients with peritoneal metastasis [J]. J Gastroenterol Hepatol, 2009, 24(5): 815-820.
40.	Llovet JM, Lencioni R. mRECIST for HCC: performance and novel refinements [J]. J Hepatol, 2020, 72(2): 288-306.
41.	Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) [J]. Eur J Cancer, 2009, 45(2): 228-247.
42.	Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma [J]. Semin Liver Dis, 2010, 30(1): 52-60.
43.	Aslam A, Chernyak V, Tang A, et al. CT/MRI LI-RADS 2024 update: treatment response assessment [J/OL]. Radiology, 2024, 313(2): e232408. doi: 10.1148/radiol.232408.
44.	Gordan JD, Kennedy EB, Abou-Alfa GK, et al. Systemic therapy for advanced hepatocellular carcinoma: ASCO guideline update [J]. J Clin Oncol, 2024, 42(15): 1830-1850.
45.	Vogel A, Chan SL, Dawson LA, et al. Hepatocellular carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up [J]. Ann Oncol, 2025, 36(5): 491-506.
46.	Singal AG, Llovet JM, Yarchoan M, et al. AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma [J]. Hepatology, 2023, 78(6): 1922-1965.
47.	Rose MG, Kennedy EB, Abou-Alfa GK, et al. Systemic therapy for advanced hepatocellular carcinoma: ASCO guideline update clinical insights [J]. JCO Oncol Pract, 2024, 20(8): 1035-1039.
48.	Lau G, Obi S, Zhou J, et al. APASL clinical practice guidelines on systemic therapy for hepatocellular carcinoma-2024 [J]. Hepatol Int, 2024, 18(6): 1661-1683.
49.	Cheng AL, Qin S, Ikeda M, et al. Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma [J]. J Hepatol, 2022, 76(4): 862-873.
50.	Yau T, Galle PR, Decaens T, et al. Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial [J]. Lancet, 2025, 405(10492): 1851-1864.
51.	Qin S, Gu S, Chan SL, et al. Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): final analysis of a randomised, open-label, international, phase 3 study [J]. Lancet Oncol, 2025, 26(12): 1598-1611.
52.	Ren Z, Xu J, Bai Y, et al. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study [J]. Lancet Oncol, 2021, 22(7): 977-990.
53.	Zhao C, Zhang Y, Wang G, et al. Finotonlimab (PD-1 inhibitor) plus bevacizumab (bevacizumab biosimilar) as first-tier therapy for late-stage hepatocellular carcinoma: a randomized phase 2/3 trial [J/OL]. Signal Transduct Target Ther, 2025, 10(1): 249. doi: 10.1038/s41392-025-02333-5.
54.	Shi Y, Han G, Zhou J, et al. Toripalimab plus bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma (HEPATORCH): a randomised, open-label, phase 3 trial [J]. Lancet Gastroenterol Hepatol, 2025, 10(7): 658-670.
55.	Zhou J, Bai L, Luo J, et al. Anlotinib plus penpulimab versus sorafenib in the first-line treatment of unresectable hepatocellular carcinoma (APOLLO): a randomised, controlled, phase 3 trial [J]. Lancet Oncol, 2025, 26(6): 719-731.
56.	Sun J, Li Q, Bai X, et al. Chinese expert consensus on clinical application of molecularly targeted drugs for hepatocellular carcinoma (2022 edition) [J]. Chin Med J (Engl), 2024, 137(21): 2630-2632.
57.	Qin S, Kudo M, Meyer T, et al. Tislelizumab vs sorafenib as first-line treatment for unresectable hepatocellular carcinoma: a phase 3 randomized clinical trial [J]. JAMA Oncol, 2023, 9(12): 1651-1659.
58.	Qin S, Bai Y, Lim HY, et al. Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia [J]. J Clin Oncol, 2013, 31(28): 3501-3508.
59.	Bruix J, Qin S, Merle P, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial [J]. Lancet, 2017, 389(10064): 56-66.
60.	Qin S, Li Q, Gu S, et al. Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial [J]. Lancet Gastroenterol Hepatol, 2021, 6(7): 559-568.
61.	Zhu AX, Kang Y, Yen C, et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial [J]. Lancet Oncol, 2019, 20(2): 282-296.
62.	Abou-Alfa GK, Meyer T, Cheng AL, et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma [J]. N Engl J Med, 2018, 379(1): 54-63.
63.	Qin S, Chen Z, Fang W, et al. Pembrolizumab versus placebo as second-line therapy in patients from asia with advanced hepatocellular carcinoma: a randomized, double-blind, phase Ⅲ trial [J]. J Clin Oncol, 2023, 41(7): 1434-1443.
64.	Qin S, Ren Z, Meng Z, et al. Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial [J]. Lancet Oncol, 2020, 21(4): 571-580.
65.	Ren Z, Ducreux M, Abou-Alfa GK, et al. Tislelizumab in patients with previously treated advanced hepatocellular carcinoma (RATIONALE-208): a multicenter, non-randomized, open-label, phase 2 trial [J]. Liver Cancer, 2023, 12(1): 72-84.
66.	Xu J, Shen J, Gu S, et al. Camrelizumab in combination with apatinib in patients with advanced hepatocellular carcinoma (RESCUE): a nonrandomized, open-label, phase Ⅱ trial [J]. Clin Cancer Res, 2021, 27(4): 1003-1011.
67.	Yau T, Kang YK, Kim TY, et al. Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib: the CheckMate 040 randomized clinical trial [J/OL]. JAMA Oncol, 2020, 6(11): e204564. doi: 10.1001/jamaoncol.2020.4564.
68.	Qin S, Chan SL, Gu S, et al. Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study [J]. Lancet, 2023, 402(10408): 1133-1146.
69.	Lu LC, Hsu C, Shao YY, et al. Differential organ-specific tumor response to immune checkpoint inhibitors in hepatocellular carcinoma [J]. Liver Cancer, 2019, 8(6): 480-490.
70.	Kim HS, Hong JY, Cheon J, et al. Different organ-specific response to nivolumab to determine the survival outcome of patients with advanced hepatocellular carcinoma (aHCC) [J/OL]. J Clin Oncol, 2020, 38(15_suppl): 4584. doi: 10.1200/JCO.2020.38.15_suppl.4584.
71.	Sun J, Mao F, Liu C, et al. Combined FOLFOX4 with all-trans retinoic acid versus FOLFOX4 with placebo in treatment of advanced hepatocellular carcinoma with extrahepatic metastasis: a randomized, double-blind comparative study [J/OL]. Signal Transduct Target Ther, 2023, 8(1): 368. doi: 10.1038/s41392-023-01604-3.
72.	He M, Huang Y, Du Z, et al. Lenvatinib, toripalimab plus FOLFOX chemotherapy in hepatocellular carcinoma patients with extrahepatic metastasis: a biomolecular exploratory, phase Ⅱ trial (LTSC) [J]. Clin Cancer Res, 2023, 29(24): 5104-5115.
73.	Liu TH, Chen SC, Rau KM, et al. Outcomes of post-immunotherapy durable responders of advanced hepatocellular carcinoma-with emphasis on locoregional therapy for oligoprogression [J]. Liver Cancer, 2024, 13(5): 509-521.
74.	Leng B, Wang H, Ge Y, et al. Maintaining first-line therapy plus radiation therapy may prolong progression-free survival and delay second-line therapy for oligoprogressive hepatocellular carcinoma [J]. Int J Radiat Oncol Biol Phys, 2025, 122(2): 325-338.
75.	He Y, Huang X, Huang X, et al. GraftPD-L1 as a predictive marker for rejection in PD-1 inhibitor therapy forrecurrent liver tumors after transplant: a prospective pilot trialjl [J]. LiverTranspl, 2026, 32(2): 135-143.
76.	蔡定芳. 病證辨治創建中國中西結合臨床醫學體系 [J]. 中國中西醫結合雜志, 2019, 39(9): 1034-1035.
77.	蔡定芳. 論病證結合臨床診療模式 [J]. 中國中西醫結合雜志, 2019, 39(2): 133-135.
78.	Sun Y, Qin S, Li W, et al. A randomized, double-blinded, phase Ⅲ study of icaritin versus huachashu as the first-line therapy in biomarker-enriched HBV-related advanced hepatocellular carcinoma with poor conditions: Interim analysis result [J]. J Clin Oncol, 2021, 39(15_suppl): 4077. doi: 10.1200/JCO.2021.39.15_suppl.407.
79.	唐亦非, 朱曉駿, 黃凌鷹, 等. 槐耳顆粒聯合索拉非尼治療晚期肝癌的臨床研究 [J]. 現代藥物與臨床, 2018, 33(7): 1732-1735.
80.	Gao H, He J, Cheng CS, et al. Unresectable hepatocellular carcinoma: transarterial chemoembolisation plus Huachansu - a single-center randomised controlled trial [J/OL]. BMJ Support Palliat Care, 2023, 14(e2): e003870. doi: 10.1136/spcare-2022-003870.
81.	成遠, 華海清. 欖香烯治療原發性肝癌的研究進展 [J]. 臨床腫瘤學雜志, 2017, 22(10): 950-953.
82.	高繼良. 肝復樂方劑治療晚期原發性肝癌的前瞻性、隨機對照臨床研究 [J]. 中國中藥雜志, 2014, 39(12): 2367-2369.
83.	Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial [J]. Lancet, 2018, 391(10126): 1163-1173.
84.	Kim S, Lee J, Rim CH. Local Treatment of hepatocellular carcinoma with oligometastases: a systematic review and meta-analysis [J/OL]. Cancers (Basel), 2023, 15(13): 3467. doi: 10.3390/cancers15133467.
85.	Yoon YS, Kim HK, Kim J, et al. Long-term survival and prognostic factors after pulmonary metastasectomy in hepatocellular carcinoma [J]. Ann Surg Oncol, 2010, 17(10): 2795-2801.
86.	Kitano K, Murayama T, Sakamoto M, et al. Outcome and survival analysis of pulmonary metastasectomy for hepatocellular carcinoma [J]. Eur J Cardiothorac Surg, 2012, 41(2): 376-382.
87.	Emmamally M, Sobnach S, Khan R, et al. Prevalence, management and outcomes of pulmonary metastases in hepatocellular carcinoma: a systematic review and meta-analysis [J]. HPB (Oxford), 2024, 26(11): 1339-1348.
88.	Ha TY, Hwang S, Ahn CS, et al. Resection of metachronous adrenal metastasis after liver resection and transplantation for hepatocellular carcinoma [J]. Dig Surg, 2014, 31(6): 428-435.
89.	Staubitz JI, Hoppe-Lotichius M, Baumgart J, et al. Survival after adrenalectomy for metastatic hepatocellular carcinoma: a 25-year institutional experience [J]. World J Surg, 2021, 45(4): 1118-1125.
90.	Kim K, Kim TH, Kim TH, et al. Efficacy of local therapy for oligometastatic hepatocellular carcinoma: a propensity score matched analysis [J]. J Hepatocell Carcinoma, 2021, 8: 35-44.
91.	Kim TH, Nam TK, Yoon SM, et al. Stereotactic ablative radiotherapy for oligometastatic hepatocellular carcinoma: a multi-institutional retrospective study (KROG 20-04) [J/OL]. Cancers (Basel), 2022, 14(23): 5848. doi: 10.3390/cancers14235848.
92.	Pan T, Xie QK, Lv N, et al. Percutaneous CT-guided radiofrequency ablation for lymph node oligometastases from hepatocellular carcinoma: a propensity score-matching analysis [J]. Radiology, 2017, 282(1): 259-270.
93.	Park BK. Percutaneous Adrenal Radiofrequency ablation: a short review for endocrinologists [J]. Endocrinol Metab (Seoul), 2020, 35(4): 750-755.
94.	de Baere T, Deschamps F. Treatment of hepatic and pulmonary metastases with radiofrequency [J]. Diagn Interv Imaging, 2014, 95(7-8): 683-688.
95.	Narayanan G, Gentile NT, Gu K, et al. Minimally invasive image-guided percutaneous irreversible electroporation of adrenal metastases [J]. Cardiovasc Intervent Radiol, 2025, 48(1): 77-83.
96.	Song Z, Zheng X, Wang H, et al. Effectiveness and safety of systemic therapy and stereotactic body radiotherapy in oligoprogressive and oligometastatic hepatocellular carcinoma [J]. J Hepatocell Carcinoma, 2025, 12: 1097-1110.
97.	Cheng X, Li J, Li Y, et al. Efficacy of stereotactic body radiotherapy in hepatocellular carcinoma with adrenal metastases: a retrospective analysis [J]. J Gastrointest Oncol, 2025, 16(4): 1610-1621.
98.	He C, Liu Y, Li Y, et al. Efficacy and safety of computed tomography-guided ¹²⁵I brachytherapy for lymph node metastatic from hepatocellular carcinoma [J]. J Cancer Res Ther, 2018, 14(4): 754-759.
99.	Zhang W, Wu L, Chen L, et al. The efficacy and safety of transarterial chemoembolization plus Iodine 125 seed implantation in the treatment of hepatocellular carcinoma with oligometastases: a case series reports [J/OL]. Front Oncol, 2022, 12: 828850. doi: 10.3389/fonc.2022.828850.
100.	Zhang L, Chen LH, Wang J, et al. CT-guided radioactive ¹²⁵I seed implantation treatment of multiple pulmonary metastases of hepatocellular carcinoma [J]. Clin Radiol, 2014, 69(6): 624-629.
101.	Lin ZY, Yang JY, Chen J, et al. Evaluating the effectiveness of computed tomography-guided ¹²⁵I seed interstitial implantation in patients with secondary adrenal carcinoma [J]. J Cancer Res Ther, 2019, 15(4): 813-817.
102.	Kim B, Moon MH, Moon SW. Prognostic factors of pulmonary metastasectomy for oligometastatic hepatocellular carcinoma spread to the lungs [J/OL]. J Clin Med, 2024, 13(14): 4241. doi: 10.3390/jcm13144241.
103.	Langan RC, Goodbred AJ. Pulmonary nodules: common questions and answers [J]. Am Fam Physician, 2023, 107(3): 282-291.
104.	Shin YS, Yun JK, Jung J, et al. Comparison of metastasectomy and stereotactic body radiation therapy for pulmonary oligometastasis from hepatocellular carcinoma: a propensity score-weighted analysis [J]. Int J Radiat Oncol Biol Phys, 2025, 121(2): 432-441.
105.	Bao Y, Yang Z, Yang Y, et al. Analysis of prognostic factors related to pulmonary metastasectomy for hepatocellular carcinoma following liver resection [J/OL]. Discov Oncol, 2026, 17(1): 445. doi: 10.1007/s12672-026-04606-z.
106.	Yang X, Xu H, Zuo B, et al. Downstaging and resection of hepatocellular carcinoma in patients with extrahepatic metastases after stereotactic therapy [J]. Hepatobiliary Surg Nutr, 2021, 10(4): 434-442.
107.	Berger Y, Spivack JH, Heskel M, et al. Extrahepatic metastasectomy for hepatocellular carcinoma: predictors of long-term survival [J]. J Surg Oncol, 2016, 114(4): 469-474.
108.	Lee HP, Yun JK, Jung HS, et al. Surgical outcomes of pulmonary metastasectomy in hepatocellular carcinoma patients according to approach method: thoracoscopic versus open approach [J/OL]. World J Surg Oncol, 2021, 19(1): 33. doi: 10.1186/s12957-021-02138-0.
109.	Kuo TM, Chang KM, Cheng TI, et al. Clinical factors predicting better survival outcome for pulmonary metastasectomy of hepatocellular carcinoma [J]. Liver Cancer, 2017, 6(4): 297-306.
110.	Tree AC, Khoo VS, Eeles RA, et al. Stereotactic body radiotherapy for oligometastases [J]. Lancet Oncol, 2013, 14(1): e28-e37.
111.	Christ SM, Alongi F, Ricardi U, et al. Cancer-specific dose and fractionation schedules in stereotactic body radiotherapy for oligometastatic disease: an interim analysis of the EORTC-ESTRO E2-RADIatE OligoCare study [J/OL]. Radiother Oncol, 2024, 195: 110235. doi: 10.1016/j.radonc.2024.110235.
112.	Bezjak A, Paulus R, Gaspar LE, et al. Safety and efficacy of a five-fraction stereotactic body radiotherapy schedule for centrally located non-small-cell lung cancer: NRG Oncology/RTOG 0813 Trial [J]. J Clin Oncol, 2019, 37(15): 1316-1325.
113.	Keall PJ, Mageras GS, Balter JM, et al. The management of respiratory motion in radiation oncology report of AAPM Task Group 76 [J]. Med Phys, 2006, 33(10): 3874-3900.
114.	Meyers SM, Kisling K, Atwood TF, et al. A standardized workflow for respiratory-gated motion management decision-making [J/OL]. J Appl Clin Med Phys, 2022, 23(8): e13705. doi: 10.1002/acm2.13705.
115.	Xi M, Liu MZ, Deng XW, et al. Defining internal target volume (ITV) for hepatocellular carcinoma using four-dimensional CT [J]. Radiother Oncol, 2007, 84(3): 272-278.
116.	Sterzing F, Brunner TB, Ernst I, et al. Stereotactic body radiotherapy for liver tumors: principles and practical guidelines of the DEGRO Working Group on Stereotactic Radiotherapy [J]. Strahlenther Onkol, 2014, 190(10): 872-881.
117.	葉欣, 范衛君, 王徽, 等. 熱消融治療原發性和轉移性肺部腫瘤專家共識 (2017年版) [J]. 中國肺癌雜志, 2017, 20(7): 433-445.
118.	Shiina S, Tateishi R, Choi JI, et al. Asian conference on tumor ablation guidelines for hepatocellular carcinoma [J]. Liver Cancer, 2025, 14(5): 651-678.
119.	Han S, Sung PS, Park SY, et al. Local ablation for hepatocellular carcinoma: 2024 expert consensus-based practical recommendation of the Korean Liver Cancer Association [J]. J Liver Cancer, 2024, 24(2): 131-144.
120.	Páez-Carpio A, Gómez FM, Isus Olivé G, et al. Image-guided percutaneous ablation for the treatment of lung malignancies: current state of the art [J/OL]. Insights Imaging, 2021, 12(1): 57. doi: 10.1186/s13244-021-00997-5.
121.	Zupanic A, Kos B, Miklavcic D. Treatment planning of electroporation-based medical interventions: electrochemotherapy, gene electrotransfer and irreversible electroporation [J]. Phys Med Biol, 2012, 57(17): 5425-5440.
122.	Miller L, Leor J, Rubinsky B. Cancer cells ablation with irreversible electroporation [J]. Technol Cancer Res Treat, 2005, 4(6): 699-705.
123.	Pistorius GA, Alexander C, Krisch CM, et al. Local platelet trapping as the cause of thrombocytopenia after hepatic cryotherapy [J]. World J Surg, 2005, 29(5): 657-660; discussion 661.
124.	Yuan Z, Liu B, Hu C, et al. Clinical outcomes of percutaneous thermal ablation for pulmonary metastases from hepatocellular carcinoma: a retrospective study [J]. Int J Hyperthermia, 2020, 37(1): 651-659.
125.	Hiraki T, Yamakado K, Ikeda O, et al. Percutaneous radiofrequency ablation for pulmonary metastases from hepatocellular carcinoma: results of a multicenter study in Japan [J]. J Vasc Interv Radiol, 2011, 22(6): 741-748.
126.	Zhou Q, Li R, Wu S, et al. Metastasis-directed ablation of hepatocellular carcinoma with pulmonary oligometastases: a long-term multicenter study [J]. Radiol Med, 2025, 130(1): 25-36.
127.	Zuo T, Lin W, Liu F, et al. Artificial pneumothorax improves radiofrequency ablation of pulmonary metastases of hepatocellular carcinoma close to mediastinum [J/OL]. BMC Cancer, 2021, 21(1): 505. doi: 10.1186/s12885-021-08223-7.
128.	Chen J, Liu J, Zhang X, et al. Verteporfin-loaded hydrogel targeting YAP-mediated MDSCs recruitment for the treatment of residual tumors after incomplete radiofrequency ablation [J]. Theranostics, 2026, 16(5): 2372-2387.
129.	Xiang Z, Bai M, Li G, et al. Safety and efficacy of ¹²⁵I brachytherapy for bilateral lung recurrences from hepatocellular carcinoma after resection or ablation [J]. J Cancer Res Clin Oncol, 2019, 145(7): 1907-1916.
130.	Li C, Zhang F, Zhang W, et al. Feasibility of (125)I brachytherapy combined with sorafenib treatment in patients with multiple lung metastases after liver transplantation for hepatocellular carcinoma [J]. J Cancer Res Clin Oncol, 2010, 136(11): 1633-1640.
131.	Yang C, He C, Yu S, et al. Effects of iodine-125 seed brachytherapy on patients with heterochronous pulmonary metastasis from hepatocellular carcinoma: a propensity score matching study [J]. J Cancer Res Ther, 2023, 19(4): 957-963.
132.	Boas FE, Kemeny NE, Sofocleous CT, et al. Bronchial or pulmonary artery chemoembolization for unresectable and unablatable lung metastases: a phase Ⅰ clinical trial [J]. Radiology, 2021, 301(2): 474-484.
133.	Kim S, Kim JH, Ko GY, et al. Bronchial artery embolization for hemoptysis caused by metastatic hepatocellular carcinoma [J/OL]. Sci Rep, 2022, 12(1): 6906. doi: 10.1038/s41598-022-10972-9.
134.	Nezami N, Georgiades C, Hong KK, et al. Bronchial artery chemoembolization with radiopaque doxorubicin eluding beads in patients with malignant hemoptysis from metastatic lung cancer [J/OL]. Technol Cancer Res Treat, 2022, 21: 15330338221131167. doi: 10.1177/15330338221131167.
135.	Fukutomi M, Yokota M, Chuman H, et al. Increased incidence of bone metastases in hepatocellular carcinoma [J]. Eur J Gastroenterol Hepatol, 2001, 13(9): 1083-1088.
136.	Goodwin CR, Yanamadala V, Ruiz-Valls A, et al. A systematic review of metastatic hepatocellular carcinoma to the spine [J]. World Neurosurg, 2016, 91: 510-517. e514.
137.	Hawkins JE, Dworzynski K, Haden N, et al. Spinal metastases and metastatic spinal cord compression: summary of updated NICE guidance [J/OL]. BMJ, 2023, 383: 1973. doi: 10.1136/bmj.p1973.
138.	Tokuhashi Y, Matsuzaki H, Oda H, et al. A revised scoring system for preoperative evaluation of metastatic spine tumor prognosis [J]. Spine (Phila Pa 1976), 2005, 30(19): 2186-2191.
139.	He J, Shi S, Ye L, et al. A randomized trial of conventional fraction versus hypofraction radiotherapy for bone metastases from hepatocellular carcinoma [J]. J Cancer, 2019, 10(17): 4031-4037.
140.	Alcorn S, Cortés áA, Bradfield L, et al. External beam radiation therapy for palliation of symptomatic bone metastases: an ASTRO Clinical Practice Guideline [J]. Pract Radiat Oncol, 2024, 14(5): 377-397.
141.	National Institute for Health and Care Excellence. Spinal metastases and metastatic spinal cord compression: NICE guideline NG234 [M/OL]. London: National Institute for Health and Care Excellence, 2023, (2023-09-06) [2026-09-01] https://www.nice.org.uk/guidance/ng234.
142.	Golimbu C, Firooznia H, Rafii M. Hepatocellular carcinoma with skeletal metastasis [J]. Radiology, 1985, 154(3): 617-618.
143.	He J, Zeng ZC, Tang ZY, et al. Clinical features and prognostic factors in patients with bone metastases from hepatocellular carcinoma receiving external beam radiotherapy [J]. Cancer, 2009, 115(12): 2710-2720.
144.	Jung IH, Yoon SM, Kwak J, et al. High-dose radiotherapy is associated with better local control of bone metastasis from hepatocellular carcinoma [J]. Oncotarget, 2017, 8(9): 15182-15192.
145.	Choi C, Seong J. Predictive factors of palliative radiotherapy response and survival in patients with spinal metastases from hepatocellular carcinoma [J]. Gut Liver, 2015, 9(1): 94-102.
146.	Guninski RS, Cuccia F, Alongi F, et al. Efficacy and safety of SBRT for spine metastases: a systematic review and meta-analysis for preparation of an ESTRO practice guideline [J/OL]. Radiother Oncol, 2024, 190: 109969. doi: 10.1016/j.radonc.2023.109969.
147.	Bindels BJJ, Mercier C, Gal R, et al. Stereotactic body and conventional radiotherapy for painful bone metastases: a systematic review and meta-analysis [J/OL]. JAMA Netw Open, 2024, 7(2): e2355409. doi: 10.1001/jamanetworkopen.2023.55409.
148.	Lee E, Kim TG, Park HC, et al. Clinical outcomes of stereotactic body radiotherapy for spinal metastases from hepatocellular carcinoma [J]. Radiat Oncol J, 2015, 33(3): 217-225.
149.	Yoo GS, Park HC, Yu JI, et al. Stereotactic ablative body radiotherapy for spinal metastasis from hepatocellular carcinoma: its oncologic outcomes and risk of vertebral compression fracture [J]. Oncotarget, 2017, 8(42): 72860-72871.
150.	Seong J, Koom WS, Park HC. Radiotherapy for painful bone metastases from hepatocellular carcinoma [J]. Liver Int, 2005, 25(2): 261-265.
151.	Bauer H, Tomita K, Kawahara N, et al. Surgical strategy for spinal metastases [J]. Spine (Phila Pa 1976), 2002, 27(10): 1124-1126.
152.	Fisher CG, DiPaola CP, Ryken TC, et al. A novel classification system for spinal instability in neoplastic disease: an evidence-based approach and expert consensus from the Spine Oncology Study Group [J]. Spine (Phila Pa 1976), 2010, 35(22): E1221-E1229.
153.	Tokuhashi Y, Matsuzaki H, Toriyama S, et al. Scoring system for the preoperative evaluation of metastatic spine tumor prognosis [J]. Spine (Phila Pa 1976), 1990, 15(11): 1110-1113.
154.	Bilsky MH, Laufer I, Fourney DR, et al. Reliability analysis of the epidural spinal cord co: mpression scale [J]. J Neurosurg Spine, 2010, 13(3): 324-328.
155.	Mirels H. Metastatic disease in long bones. A proposed scoring system for diagnosing impending pathologic fractures [J]. Clin Orthop Relat Res, 1989(249): 256-264.
156.	Van der Linden YM, Dijkstra PDS, Kroon HM, et al. Comparative analysis of risk factors for pathological fracture with femoral metastases [J]. J Bone Joint Surg Br, 2004, 86(4): 566-573.
157.	Gonzalez MR, Bryce-Alberti M, Pretell-Mazzini J. Management of long bones metastatic disease: concepts that we all know but not always remember [J]. Orthop Res Rev, 2022, 14: 393-406.
158.	Baba K, Kaida H, Hattori C, et al. Tumoricidal effect and pain relief after concurrent therapy by strontium-89 chloride and zoledronic acid for bone metastases [J]. Hell J Nucl Med, 2018, 21(1): 15-23.
159.	付欽卿, 袁欽詩, 楊夏欣. 放射性核素氯化鍶 (⁸⁹Sr) 聯合唑來膦酸對原發性肝癌骨轉移的療效及安全性 [J]. 肝臟, 2025, 30(2): 222-225.
160.	Naruto K, Kawaoka T, Yamasaki S, et al. Clinical outcomes of switching from zoledronic acid to denosumab for the management of severe bone metastasis from hepatocellular carcinoma: a single-center, open-label, prospective intervention trial [J]. Yonago Acta Med, 2023, 66(4): 422-431.
161.	Stopeck AT, Lipton A, Body JJ, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study [J]. J Clin Oncol, 2010, 28(35): 5132-5139.
162.	Dodd GD, Baron RL, Oliver JH, et al. Enlarged abdominal lymph nodes in end-stage cirrhosis: CT-histopathologic correlation in 507 patients [J]. Radiology, 1997, 203(1): 127-130.
163.	Yang A, Xiao W, Ju W, et al. Prevalence and clinical significance of regional lymphadenectomy in patients with hepatocellular carcinoma [J]. ANZ J Surg, 2019, 89(4): 393-398.
164.	Spoletini G, Mauro A, Caimano M, et al. The role of lymphadenectomy in the surgical treatment of hepatocellular carcinoma: a systematic review and meta-analysis [J/OL]. Cancers (Basel), 2024, 16(24): 4166. doi: 10.3390/cancers16244166.
165.	Wang Y, Li Q, Zhang L, et al. Efficacy and dose-response relationship of stereotactic body radiotherapy for abdominal lymph node metastases from hepatocellular carcinoma [J]. Oncologist, 2023, 28(6): e369-e378.
166.	Matoba M, Tsuchiya H, Kondo T, et al. Stereotactic body radiotherapy delivered with IMRT for oligometastatic regional lymph node metastases in hepatocellular carcinoma: a single-institutional study [J]. J Radiat Res, 2020, 61(5): 776-783.
167.	Utsumi M, Matsuda H, Sadamori H, et al. Resection of metachronous lymph node metastases from hepatocellular carcinoma after hepatectomy: report of four cases [J]. Acta Med Okayama, 2012, 66(2): 177-182.
168.	Yuan Z, Xing A, Zheng J, et al. Safety and technical feasibility of percutaneous ablation for lymph node metastases of hepatocellular carcinoma [J]. Int J Hyperthermia, 2019, 36(1): 160-168.
169.	Gao F, Gu Y, Huang J, et al. Radiofrequency ablation of retroperitoneal metastatic lymph nodes from hepatocellular carcinoma [J]. Acad Radiol, 2012, 19(8): 1035-1040.
170.	Parvinian A, Schmitz JJ, Welch BT, et al. A single-institution experience in percutaneous image-guided cryoablation of lymph node metastases [J]. AJR Am J Roentgenol, 2021, 217(1): 152-156.
171.	Filippiadis DK, Pua U, Georgiadi E, et al. Percutaneous ablation of metastatic lymph nodes: an insight from the comparison of efficacy and safety between cryoablation and radiofrequency ablation [J]. Cardiovasc Intervent Radiol, 2022, 45(8): 1134-1140.
172.	Huang D, Zhong Z, Zhang F, et al. Clinical outcomes and individualized seed implantation planning for iodine-125 seeds brachytherapy in lymph node metastases [J]. J Cancer, 2026, 17(3): 507-514.
173.	Momoi H, Shimahara Y, Terajima H, et al. Management of adrenal metastasis from hepatocellular carcinoma [J]. Surg Today, 2002, 32(12): 1035-1041.
174.	Xu B, Zhao X, Chen D, et al. Two-institution results of stereotactic body radiation therapy (SBRT) for treating adrenal gland metastases from liver cancer [J/OL]. BMC Cancer, 2023, 23(1): 73. doi: 10.1186/s12885-023-10519-9.
175.	Ehret F, Kaul D, Kufeld M, et al. Robotic stereotactic body radiotherapy for the management of adrenal gland metastases: a bi-institutional analysis [J]. J Cancer Res Clin Oncol, 2023, 149(3): 1095-1101.
176.	Umakoshi N, Matsui Y, Tomita K, et al. Image-guided ablation therapies for extrahepatic metastases from hepatocellular carcinoma: a review [J/OL]. Cancers (Basel), 2023, 15(14): 3665. doi: 10.3390/cancers15143665.
177.	Lyu N, Kong Y, Pan T, et al. Survival benefits of computed tomography-guided thermal ablation for adrenal metastases from hepatocellular carcinoma [J]. Int J Hyperthermia, 2019, 36(1): 1003-1011.
178.	Zhou K, Pan J, Yang N, et al. Effectiveness and safety of CT-guided percutaneous radiofrequency ablation of adrenal metastases [J/OL]. Br J Radiol, 2018, 91(1085): 20170607. doi: 10.1259/bjr.20170607.
179.	Pusceddu C, Faiella E, Cau C, et al. Computed tomography-guided cryoablation in treating adrenal metastases: a retrospective single-center study [J]. Diagn Interv Radiol, 2025, 31(4): 372-376.
180.	Aoun HD, Littrup PJ, Nahab B, et al. Percutaneous cryoablation of adrenal metastases: technical feasibility and safety [J]. Abdom Radiol (NY), 2021, 46(6): 2805-2813.
181.	Park BK, Fujimori M, Shen SH, et al. Asian Conference on Tumor Ablation Guidelines for Adrenal Tumor Ablation [J]. Endocrinol Metab (Seoul), 2021, 36(3): 553-563.
182.	Welch BT, Atwell TD, Nichols DA, et al. Percutaneous image-guided adrenal cryoablation: procedural considerations and technical success [J]. Radiology, 2011, 258(1): 301-307.
183.	Hou Y, Liu R, Cui Y, et al. Short-term effectiveness and safety of CT-guided radioactive iodine-125 seed implantation for treatment of adrenal metastases [J]. J Contemp Brachytherapy, 2022, 14(2): 148-156.
184.	Yan G, Zhang K, Yan L, et al. Long-term survival outcomes following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal metastasis of hepatocellular carcinoma patients [J/OL]. World J Surg Oncol, 2024, 22(1): 144. doi: 10.1186/s12957-024-03426-1.
185.	Xia F, Ndhlovu E, Zhang M, et al. Ruptured hepatocellular carcinoma: current status of Research [J/OL]. Front Oncol, 2022, 12: 848903. doi: 10.3389/fonc.2022.848903.
186.	Healy JC. Detection of peritoneal metastases [J]. Cancer Imaging, 2001, 1(2): 4-12.
187.	Spiliotis J, Nikolaou G, Kopanakis N, et al. Hepatocellular carcinoma peritoneal metastasis: role of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) [J]. Gulf J Oncolog, 2017, 1(24): 20-23.
188.	Tabrizian P, Franssen B, Jibara G, et al. Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy in patients with peritoneal hepatocellular carcinoma [J]. J Surg Oncol, 2014, 110(7): 786-790.
189.	Okuda T, Hayashi N, Takahashi M, et al. Clinical outcomes of brain metastases from hepatocellular carcinoma: a multicenter retrospective study and a literature review [J]. Int J Clin Oncol, 2018, 23(6): 1095-1100.
190.	Choi HJ, Cho BC, Sohn JH, et al. Brain metastases from hepatocellular carcinoma: prognostic factors and outcome: brain metastasis from HCC [J]. J Neurooncol, 2009, 91(3): 307-313.
191.	Park ES, Kwon DH, Park JB, et al. Gamma knife surgery for treating brain metastases arising from hepatocellular carcinomas [J]. J Neurosurg, 2014, 121 Suppl: 102-109.
192.	Mustafayev K, Mustafayev FNA, Ganiyani MA, et al. Treatment modalities and survival outcomes in patients with hepatocellular carcinoma with brain metastases (HCC-BM): a large national study [J]. J Clin Oncol, 2025, 43(16_suppl): e14007. doi: 10.1200/JCO.2025.43.16_suppl.e14007.
193.	Schiff D, Messersmith H, Brastianos PK, et al. Radiation therapy for brain metastases: ASCO guideline endorsement of ASTRO guideline [J]. J Clin Oncol, 2022, 40(20): 2271-2276.
194.	Cook AM, Morgan Jones G, Hawryluk GWJ, et al. Guidelines for the acute treatment of cerebral edema in neurocritical care patients [J]. Neurocrit Care, 2020, 32(3): 647-666.
195.	Le Rhun E, Guckenberger M, Smits M, et al. EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours [J]. Ann Oncol, 2021, 32(11): 1332-1347.
196.	Ye K, Fan Q, Yuan M, et al. Prognostic value of postoperative circulating tumor DNA in patients with early- and intermediate-stage hepatocellular carcinoma [J/OL]. Front Oncol, 2022, 12: 834992. doi: 10.3389/fonc.2022.834992.
197.	Ren Q, Li S, Zhong G, et al. Non-invasive tumor-na?ve minimal residual disease detection of liver cancer by incorporating circulating tumor DNA features and alpha-fetoprotein: a prospective study [J/OL]. Cancer Med, 2024, 13(24): e70511. doi: 10.1002/cam4.70511.
198.	Ji GW, Zhu FP, Xu Q, et al. Radiomic features at contrast-enhanced CT predict recurrence in early stage hepatocellular carcinoma: a multi-institutional study [J]. Radiology, 2020, 294(3): 568-579.
199.	Hou S, Hu S, Wu Q, et al. Efficacy and safety of stereotactic body radiation therapy combined with targeted agents and immunotherapies in hepatocellular carcinoma: a systematic review and meta-analysis [J/OL]. BMC Cancer, 2025, 25(1): 1602. doi: 10.1186/s12885-025-15061-4.
200.	Shi D, Shi Y, Kaseb AO, et al. Chimeric antigen receptor-glypican-3 t-cell therapy for advanced hepatocellular carcinoma: results of phase Ⅰ trials [J]. Clin Cancer Res, 2020, 26(15): 3979-3989.
201.	Fu Y, Urban DJ, Nani RR, et al. Glypican-3-specific antibody drug conjugates targeting hepatocellular carcinoma [J]. Hepatology, 2019, 70(2): 563-576.
202.	Heo J, Reid T, Ruo L, et al. Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer [J]. Nat Med, 2013, 19(3): 329-336.
203.	Shen X, Zhao D, Wang F, et al. Dietary intervention reshapes gut microbiota and lipid metabolism to enhance anti-tumor immunity and prognosis in hepatocellular carcinoma: a randomized controlled trial [J/OL]. BMC Cancer, 2026, 26(1): 42. doi: 10.1186/s12885-025-15325-z.

1. Han B, Zheng R, Zeng H, et al. Cancer incidence and mortality in China, 2022 [J]. J Natl Cancer Cent, 2024, 4(1): 47-53.
2. Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. CA Cancer J Clin, 2024, 74(3): 229-263.
3. Sung H, Filho AM, Laversanne M, et al. Global cancer statistics 2024: GLOBOCAN estimates of incidence and mortality worldwide for 34 cancers in 186 countries [J/OL]. CA Cancer J Clin, 2026, 76(4): e70090. doi: 10.3322/caac.70090.
4. 李響, 李恒希, 鄭榮壽, 等. 2024全球癌癥統計數據解讀: 中國與全球對比 [J]. 中國普外基礎與臨床雜志, 2026, 33(8): 1009-1017.
5. Wen B, Te L, Bai C, et al. Relative contribution of hepatitis B and C viruses in primary liver cancer in China: a systematic review and meta-analysis [J/OL]. J Infect, 2024, 89(6): 106298. doi: 10.1016/j.jinf.2024.106298.
6. Li Q, Ding C, Cao M, et al. Global epidemiology of liver cancer 2022: an emphasis on geographic disparities [J]. Chin Med J (Engl), 2024, 137(19): 2334-2342.
7. Amin MB, Greene FL, Edge SB, et al. The Eighth Edition AJCC Cancer Staging Manual: continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging [J]. CA Cancer J Clin, 2017, 67(2): 93-99.
8. 中華人民共和國國家衛生健康委員會醫政司. 原發性肝癌診療指南 (2024年版) [J]. 中國普通外科雜志, 2024, 33(4): 475-530.
9. Reig M, Sanduzzi-Zamparelli M, Forner A, et al. BCLC strategy for prognosis prediction and treatment recommendations: the 2026 update [J]. J Hepatol, 2026, 84(3): 631-654.
10. Uka K, Aikata H, Takaki S, et al. Clinical features and prognosis of patients with extrahepatic metastases from hepatocellular carcinoma [J]. World J Gastroenterol, 2007, 13(3): 414-420.
11. Uchino K, Tateishi R, Shiina S, et al. Hepatocellular carcinoma with extrahepatic metastasis: clinical features and prognostic factors [J]. Cancer, 2011, 117(19): 4475-4483.
12. 廣東省抗癌協會肝癌專業委員會, 中山大學腫瘤防治中心肝膽科. 肝癌多學科綜合治療團隊建立—廣東專家共識 (1) [J]. 中國實用外科雜志, 2014, 34(8): 732-734.
13. 中國抗癌協會肝癌專業委員會. 中國肝癌多學科綜合治療專家共識 [J]. 肝癌電子雜志, 2020, 7(4): 2-8.
14. 中國抗癌協會肝癌專業委員會. 中國肝癌多學科綜合治療專家共識 (2025年版) [J]. 臨床肝膽病雜志, 2025, 41(7): 1279-1286.
15. 中共中央, 國務院. 中共中央國務院印發《“健康中國2030”規劃綱要》[EB/OL]. (2016-10-25) [2026-09-02]. https://www.nhc.gov.cn/guihuaxxs/c100132/201610/cef9821abcfc4544bb27e2bc533bd7cf.shtml.
16. 中華人民共和國國家衛生健康委員會醫政司. 原發性肝癌診療指南 (2026年版) [J]. 中國普外基礎與臨床雜志, 2026, 33(4): 425-485.
17. Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations [J]. BMJ, 2008, 336(7650): 924-926.
18. Gattrell WT, Logullo P, van Zuuren EJ, et al. ACCORD (ACcurate COnsensus Reporting Document): a reporting guideline for consensus methods in biomedicine developed via a modified Delphi [J/OL]. PLoS Med, 2024, 21(1): e1004326. doi: 10.1371/journal.pmed.1004326.
19. 國家癌癥中心. 中國肝癌規范診療質量控制指標 (2022版) [J]. 肝癌電子雜志, 2022, 9(4): 1-11.
20. Cammarota A, Zanuso V, Pressiani T, et al. Assessment and monitoring of response to systemic treatment in advanced hepatocellular carcinoma: current insights [J]. J Hepatocell Carcinoma, 2022, 9: 1011-1027.
21. Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma [J]. N Engl J Med, 2020, 382(20): 1894-1905.
22. Abou-Alfa GK, Lau G, Kudo M, et al. Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma [J/OL]. NEJM Evid, 2022, 1(8): EVIDoa2100070. doi: 10.1056/EVIDoa2100070.
23. Liou TC, Shih SC, Kao CR, et al. Pulmonary metastasis of hepatocellular carcinoma associated with transarterial chemoembolization [J]. J Hepatol, 1995, 23(5): 563-568.
24. MacMahon H, Naidich DP, Goo JM, et al. Guidelines for management of incidental pulmonary nodules detected on CT images: from the Fleischner Society 2017 [J]. Radiology, 2017, 284(1): 228-243.
25. Expert Panel on Gastrointestinal Imaging; Smith EN, Bashir MR, et al. ACR appropriateness criteria^? staging and follow-up of primary liver cancer [J]. J Am Coll Radiol, 2025, 22(11S): S699-S712.
26. Lee JE, Jang JY, Jeong SW, et al. Diagnostic value for extrahepatic metastases of hepatocellular carcinoma in positron emission tomography/computed tomography scan [J]. World J Gastroenterol, 2012, 18(23): 2979-2987.
27. ?ukaszewski B, Nazar J, Goch M, et al. Diagnostic methods for detection of bone metastases [J]. Contemp Oncol (Pozn), 2017, 21(2): 98-103.
28. Zhou J, Sun H, Wang Z, et al. China Liver Cancer Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2024 Edition) [J]. Liver Cancer, 2025, 14(6): 779-835.
29. Longo V, Brunetti O, D’Oronzo S, et al. Bone metastases in hepatocellular carcinoma: an emerging issue [J]. Cancer Metastasis Rev, 2014, 33(1): 333-342.
30. Costa F, Restelli F, Innocenti N, et al. Incidence, epidemiology, radiology, and classification of metastatic spine tumors: WFNS Spine Committee recommendations [J/OL]. Neurosurg Rev, 2024, 47(1): 853. doi: 10.1007/s10143-024-03095-4. doi: 10.1007/s10143-024-03095-4.
31. Lin CY, Chen JH, Liang JA, et al. ¹⁸F-FDG PET or PET/CT for detecting extrahepatic metastases or recurrent hepatocellular carcinoma: a systematic review and meta-analysis [J]. Eur J Radiol, 2012, 81(9): 2417-2422.
32. Jiang XB, Ke C, Zhang GH, et al. Brain metastases from hepatocellular carcinoma: clinical features and prognostic factors [J/OL]. BMC Cancer, 2012, 12: 49. doi: 10.1186/1471-2407-12-49. doi: 10.1186/1471-2407-12-49.
33. Enrique GV, Irving SR, Ricardo BI, et al. Diagnosis and management of brain metastases: an updated review from a radiation oncology perspective [J/OL]. J Cancer Metastasis Treat, 2019, 5: 54. doi: 10.20517/2394-4722.2019.20. doi: 10.20517/2394-4722.2019.20.
34. Ng PR, Choi BD, Aghi MK, et al. Surgical advances in the management of brain metastases [J]. Neurooncol Adv, 2021, 3(Suppl 5): v4-v15.
35. Katyal S, Oliver JH 3rd, Peterson MS, et al. Extrahepatic metastases of hepatocellular carcinoma [J]. Radiology, 2000, 216(3): 698-703.
36. Natsuizaka M, Omura T, Akaike T, et al. Clinical features of hepatocellular carcinoma with extrahepatic metastases [J]. J Gastroenterol Hepatol, 2005, 20(11): 1781-1787.
37. Okuda K, Arakawa M, Kubo Y, et al. Right-sided pedunculated hepatocellular carcinoma: a form of adrenal metastasis [J]. Hepatology, 1998, 27(1): 81-85.
38. Da Fonseca LG, Leonardi PC, Hashizume PH, et al. A multidisciplinary approach to peritoneal metastasis from hepatocellular carcinoma: clinical features, management and outcomes [J]. Clin Exp Hepatol, 2022, 8(1): 42-48.
39. Lin CC, Liang HP, Lee HS, et al. Clinical manifestations and survival of hepatocellular carcinoma patients with peritoneal metastasis [J]. J Gastroenterol Hepatol, 2009, 24(5): 815-820.
40. Llovet JM, Lencioni R. mRECIST for HCC: performance and novel refinements [J]. J Hepatol, 2020, 72(2): 288-306.
41. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) [J]. Eur J Cancer, 2009, 45(2): 228-247.
42. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma [J]. Semin Liver Dis, 2010, 30(1): 52-60.
43. Aslam A, Chernyak V, Tang A, et al. CT/MRI LI-RADS 2024 update: treatment response assessment [J/OL]. Radiology, 2024, 313(2): e232408. doi: 10.1148/radiol.232408.
44. Gordan JD, Kennedy EB, Abou-Alfa GK, et al. Systemic therapy for advanced hepatocellular carcinoma: ASCO guideline update [J]. J Clin Oncol, 2024, 42(15): 1830-1850.
45. Vogel A, Chan SL, Dawson LA, et al. Hepatocellular carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up [J]. Ann Oncol, 2025, 36(5): 491-506.
46. Singal AG, Llovet JM, Yarchoan M, et al. AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma [J]. Hepatology, 2023, 78(6): 1922-1965.
47. Rose MG, Kennedy EB, Abou-Alfa GK, et al. Systemic therapy for advanced hepatocellular carcinoma: ASCO guideline update clinical insights [J]. JCO Oncol Pract, 2024, 20(8): 1035-1039.
48. Lau G, Obi S, Zhou J, et al. APASL clinical practice guidelines on systemic therapy for hepatocellular carcinoma-2024 [J]. Hepatol Int, 2024, 18(6): 1661-1683.
49. Cheng AL, Qin S, Ikeda M, et al. Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma [J]. J Hepatol, 2022, 76(4): 862-873.
50. Yau T, Galle PR, Decaens T, et al. Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial [J]. Lancet, 2025, 405(10492): 1851-1864.
51. Qin S, Gu S, Chan SL, et al. Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): final analysis of a randomised, open-label, international, phase 3 study [J]. Lancet Oncol, 2025, 26(12): 1598-1611.
52. Ren Z, Xu J, Bai Y, et al. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study [J]. Lancet Oncol, 2021, 22(7): 977-990.
53. Zhao C, Zhang Y, Wang G, et al. Finotonlimab (PD-1 inhibitor) plus bevacizumab (bevacizumab biosimilar) as first-tier therapy for late-stage hepatocellular carcinoma: a randomized phase 2/3 trial [J/OL]. Signal Transduct Target Ther, 2025, 10(1): 249. doi: 10.1038/s41392-025-02333-5.
54. Shi Y, Han G, Zhou J, et al. Toripalimab plus bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma (HEPATORCH): a randomised, open-label, phase 3 trial [J]. Lancet Gastroenterol Hepatol, 2025, 10(7): 658-670.
55. Zhou J, Bai L, Luo J, et al. Anlotinib plus penpulimab versus sorafenib in the first-line treatment of unresectable hepatocellular carcinoma (APOLLO): a randomised, controlled, phase 3 trial [J]. Lancet Oncol, 2025, 26(6): 719-731.
56. Sun J, Li Q, Bai X, et al. Chinese expert consensus on clinical application of molecularly targeted drugs for hepatocellular carcinoma (2022 edition) [J]. Chin Med J (Engl), 2024, 137(21): 2630-2632.
57. Qin S, Kudo M, Meyer T, et al. Tislelizumab vs sorafenib as first-line treatment for unresectable hepatocellular carcinoma: a phase 3 randomized clinical trial [J]. JAMA Oncol, 2023, 9(12): 1651-1659.
58. Qin S, Bai Y, Lim HY, et al. Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia [J]. J Clin Oncol, 2013, 31(28): 3501-3508.
59. Bruix J, Qin S, Merle P, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial [J]. Lancet, 2017, 389(10064): 56-66.
60. Qin S, Li Q, Gu S, et al. Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial [J]. Lancet Gastroenterol Hepatol, 2021, 6(7): 559-568.
61. Zhu AX, Kang Y, Yen C, et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial [J]. Lancet Oncol, 2019, 20(2): 282-296.
62. Abou-Alfa GK, Meyer T, Cheng AL, et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma [J]. N Engl J Med, 2018, 379(1): 54-63.
63. Qin S, Chen Z, Fang W, et al. Pembrolizumab versus placebo as second-line therapy in patients from asia with advanced hepatocellular carcinoma: a randomized, double-blind, phase Ⅲ trial [J]. J Clin Oncol, 2023, 41(7): 1434-1443.
64. Qin S, Ren Z, Meng Z, et al. Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial [J]. Lancet Oncol, 2020, 21(4): 571-580.
65. Ren Z, Ducreux M, Abou-Alfa GK, et al. Tislelizumab in patients with previously treated advanced hepatocellular carcinoma (RATIONALE-208): a multicenter, non-randomized, open-label, phase 2 trial [J]. Liver Cancer, 2023, 12(1): 72-84.
66. Xu J, Shen J, Gu S, et al. Camrelizumab in combination with apatinib in patients with advanced hepatocellular carcinoma (RESCUE): a nonrandomized, open-label, phase Ⅱ trial [J]. Clin Cancer Res, 2021, 27(4): 1003-1011.
67. Yau T, Kang YK, Kim TY, et al. Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib: the CheckMate 040 randomized clinical trial [J/OL]. JAMA Oncol, 2020, 6(11): e204564. doi: 10.1001/jamaoncol.2020.4564.
68. Qin S, Chan SL, Gu S, et al. Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study [J]. Lancet, 2023, 402(10408): 1133-1146.
69. Lu LC, Hsu C, Shao YY, et al. Differential organ-specific tumor response to immune checkpoint inhibitors in hepatocellular carcinoma [J]. Liver Cancer, 2019, 8(6): 480-490.
70. Kim HS, Hong JY, Cheon J, et al. Different organ-specific response to nivolumab to determine the survival outcome of patients with advanced hepatocellular carcinoma (aHCC) [J/OL]. J Clin Oncol, 2020, 38(15_suppl): 4584. doi: 10.1200/JCO.2020.38.15_suppl.4584.
71. Sun J, Mao F, Liu C, et al. Combined FOLFOX4 with all-trans retinoic acid versus FOLFOX4 with placebo in treatment of advanced hepatocellular carcinoma with extrahepatic metastasis: a randomized, double-blind comparative study [J/OL]. Signal Transduct Target Ther, 2023, 8(1): 368. doi: 10.1038/s41392-023-01604-3.
72. He M, Huang Y, Du Z, et al. Lenvatinib, toripalimab plus FOLFOX chemotherapy in hepatocellular carcinoma patients with extrahepatic metastasis: a biomolecular exploratory, phase Ⅱ trial (LTSC) [J]. Clin Cancer Res, 2023, 29(24): 5104-5115.
73. Liu TH, Chen SC, Rau KM, et al. Outcomes of post-immunotherapy durable responders of advanced hepatocellular carcinoma-with emphasis on locoregional therapy for oligoprogression [J]. Liver Cancer, 2024, 13(5): 509-521.
74. Leng B, Wang H, Ge Y, et al. Maintaining first-line therapy plus radiation therapy may prolong progression-free survival and delay second-line therapy for oligoprogressive hepatocellular carcinoma [J]. Int J Radiat Oncol Biol Phys, 2025, 122(2): 325-338.
75. He Y, Huang X, Huang X, et al. GraftPD-L1 as a predictive marker for rejection in PD-1 inhibitor therapy forrecurrent liver tumors after transplant: a prospective pilot trialjl [J]. LiverTranspl, 2026, 32(2): 135-143.
76. 蔡定芳. 病證辨治創建中國中西結合臨床醫學體系 [J]. 中國中西醫結合雜志, 2019, 39(9): 1034-1035.
77. 蔡定芳. 論病證結合臨床診療模式 [J]. 中國中西醫結合雜志, 2019, 39(2): 133-135.
78. Sun Y, Qin S, Li W, et al. A randomized, double-blinded, phase Ⅲ study of icaritin versus huachashu as the first-line therapy in biomarker-enriched HBV-related advanced hepatocellular carcinoma with poor conditions: Interim analysis result [J]. J Clin Oncol, 2021, 39(15_suppl): 4077. doi: 10.1200/JCO.2021.39.15_suppl.407.
79. 唐亦非, 朱曉駿, 黃凌鷹, 等. 槐耳顆粒聯合索拉非尼治療晚期肝癌的臨床研究 [J]. 現代藥物與臨床, 2018, 33(7): 1732-1735.
80. Gao H, He J, Cheng CS, et al. Unresectable hepatocellular carcinoma: transarterial chemoembolisation plus Huachansu - a single-center randomised controlled trial [J/OL]. BMJ Support Palliat Care, 2023, 14(e2): e003870. doi: 10.1136/spcare-2022-003870.
81. 成遠, 華海清. 欖香烯治療原發性肝癌的研究進展 [J]. 臨床腫瘤學雜志, 2017, 22(10): 950-953.
82. 高繼良. 肝復樂方劑治療晚期原發性肝癌的前瞻性、隨機對照臨床研究 [J]. 中國中藥雜志, 2014, 39(12): 2367-2369.
83. Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial [J]. Lancet, 2018, 391(10126): 1163-1173.
84. Kim S, Lee J, Rim CH. Local Treatment of hepatocellular carcinoma with oligometastases: a systematic review and meta-analysis [J/OL]. Cancers (Basel), 2023, 15(13): 3467. doi: 10.3390/cancers15133467.
85. Yoon YS, Kim HK, Kim J, et al. Long-term survival and prognostic factors after pulmonary metastasectomy in hepatocellular carcinoma [J]. Ann Surg Oncol, 2010, 17(10): 2795-2801.
86. Kitano K, Murayama T, Sakamoto M, et al. Outcome and survival analysis of pulmonary metastasectomy for hepatocellular carcinoma [J]. Eur J Cardiothorac Surg, 2012, 41(2): 376-382.
87. Emmamally M, Sobnach S, Khan R, et al. Prevalence, management and outcomes of pulmonary metastases in hepatocellular carcinoma: a systematic review and meta-analysis [J]. HPB (Oxford), 2024, 26(11): 1339-1348.
88. Ha TY, Hwang S, Ahn CS, et al. Resection of metachronous adrenal metastasis after liver resection and transplantation for hepatocellular carcinoma [J]. Dig Surg, 2014, 31(6): 428-435.
89. Staubitz JI, Hoppe-Lotichius M, Baumgart J, et al. Survival after adrenalectomy for metastatic hepatocellular carcinoma: a 25-year institutional experience [J]. World J Surg, 2021, 45(4): 1118-1125.
90. Kim K, Kim TH, Kim TH, et al. Efficacy of local therapy for oligometastatic hepatocellular carcinoma: a propensity score matched analysis [J]. J Hepatocell Carcinoma, 2021, 8: 35-44.
91. Kim TH, Nam TK, Yoon SM, et al. Stereotactic ablative radiotherapy for oligometastatic hepatocellular carcinoma: a multi-institutional retrospective study (KROG 20-04) [J/OL]. Cancers (Basel), 2022, 14(23): 5848. doi: 10.3390/cancers14235848.
92. Pan T, Xie QK, Lv N, et al. Percutaneous CT-guided radiofrequency ablation for lymph node oligometastases from hepatocellular carcinoma: a propensity score-matching analysis [J]. Radiology, 2017, 282(1): 259-270.
93. Park BK. Percutaneous Adrenal Radiofrequency ablation: a short review for endocrinologists [J]. Endocrinol Metab (Seoul), 2020, 35(4): 750-755.
94. de Baere T, Deschamps F. Treatment of hepatic and pulmonary metastases with radiofrequency [J]. Diagn Interv Imaging, 2014, 95(7-8): 683-688.
95. Narayanan G, Gentile NT, Gu K, et al. Minimally invasive image-guided percutaneous irreversible electroporation of adrenal metastases [J]. Cardiovasc Intervent Radiol, 2025, 48(1): 77-83.
96. Song Z, Zheng X, Wang H, et al. Effectiveness and safety of systemic therapy and stereotactic body radiotherapy in oligoprogressive and oligometastatic hepatocellular carcinoma [J]. J Hepatocell Carcinoma, 2025, 12: 1097-1110.
97. Cheng X, Li J, Li Y, et al. Efficacy of stereotactic body radiotherapy in hepatocellular carcinoma with adrenal metastases: a retrospective analysis [J]. J Gastrointest Oncol, 2025, 16(4): 1610-1621.
98. He C, Liu Y, Li Y, et al. Efficacy and safety of computed tomography-guided ¹²⁵I brachytherapy for lymph node metastatic from hepatocellular carcinoma [J]. J Cancer Res Ther, 2018, 14(4): 754-759.
99. Zhang W, Wu L, Chen L, et al. The efficacy and safety of transarterial chemoembolization plus Iodine 125 seed implantation in the treatment of hepatocellular carcinoma with oligometastases: a case series reports [J/OL]. Front Oncol, 2022, 12: 828850. doi: 10.3389/fonc.2022.828850.
100. Zhang L, Chen LH, Wang J, et al. CT-guided radioactive ¹²⁵I seed implantation treatment of multiple pulmonary metastases of hepatocellular carcinoma [J]. Clin Radiol, 2014, 69(6): 624-629.
101. Lin ZY, Yang JY, Chen J, et al. Evaluating the effectiveness of computed tomography-guided ¹²⁵I seed interstitial implantation in patients with secondary adrenal carcinoma [J]. J Cancer Res Ther, 2019, 15(4): 813-817.
102. Kim B, Moon MH, Moon SW. Prognostic factors of pulmonary metastasectomy for oligometastatic hepatocellular carcinoma spread to the lungs [J/OL]. J Clin Med, 2024, 13(14): 4241. doi: 10.3390/jcm13144241.
103. Langan RC, Goodbred AJ. Pulmonary nodules: common questions and answers [J]. Am Fam Physician, 2023, 107(3): 282-291.
104. Shin YS, Yun JK, Jung J, et al. Comparison of metastasectomy and stereotactic body radiation therapy for pulmonary oligometastasis from hepatocellular carcinoma: a propensity score-weighted analysis [J]. Int J Radiat Oncol Biol Phys, 2025, 121(2): 432-441.
105. Bao Y, Yang Z, Yang Y, et al. Analysis of prognostic factors related to pulmonary metastasectomy for hepatocellular carcinoma following liver resection [J/OL]. Discov Oncol, 2026, 17(1): 445. doi: 10.1007/s12672-026-04606-z.
106. Yang X, Xu H, Zuo B, et al. Downstaging and resection of hepatocellular carcinoma in patients with extrahepatic metastases after stereotactic therapy [J]. Hepatobiliary Surg Nutr, 2021, 10(4): 434-442.
107. Berger Y, Spivack JH, Heskel M, et al. Extrahepatic metastasectomy for hepatocellular carcinoma: predictors of long-term survival [J]. J Surg Oncol, 2016, 114(4): 469-474.
108. Lee HP, Yun JK, Jung HS, et al. Surgical outcomes of pulmonary metastasectomy in hepatocellular carcinoma patients according to approach method: thoracoscopic versus open approach [J/OL]. World J Surg Oncol, 2021, 19(1): 33. doi: 10.1186/s12957-021-02138-0.
109. Kuo TM, Chang KM, Cheng TI, et al. Clinical factors predicting better survival outcome for pulmonary metastasectomy of hepatocellular carcinoma [J]. Liver Cancer, 2017, 6(4): 297-306.
110. Tree AC, Khoo VS, Eeles RA, et al. Stereotactic body radiotherapy for oligometastases [J]. Lancet Oncol, 2013, 14(1): e28-e37.
111. Christ SM, Alongi F, Ricardi U, et al. Cancer-specific dose and fractionation schedules in stereotactic body radiotherapy for oligometastatic disease: an interim analysis of the EORTC-ESTRO E2-RADIatE OligoCare study [J/OL]. Radiother Oncol, 2024, 195: 110235. doi: 10.1016/j.radonc.2024.110235.
112. Bezjak A, Paulus R, Gaspar LE, et al. Safety and efficacy of a five-fraction stereotactic body radiotherapy schedule for centrally located non-small-cell lung cancer: NRG Oncology/RTOG 0813 Trial [J]. J Clin Oncol, 2019, 37(15): 1316-1325.
113. Keall PJ, Mageras GS, Balter JM, et al. The management of respiratory motion in radiation oncology report of AAPM Task Group 76 [J]. Med Phys, 2006, 33(10): 3874-3900.
114. Meyers SM, Kisling K, Atwood TF, et al. A standardized workflow for respiratory-gated motion management decision-making [J/OL]. J Appl Clin Med Phys, 2022, 23(8): e13705. doi: 10.1002/acm2.13705.
115. Xi M, Liu MZ, Deng XW, et al. Defining internal target volume (ITV) for hepatocellular carcinoma using four-dimensional CT [J]. Radiother Oncol, 2007, 84(3): 272-278.
116. Sterzing F, Brunner TB, Ernst I, et al. Stereotactic body radiotherapy for liver tumors: principles and practical guidelines of the DEGRO Working Group on Stereotactic Radiotherapy [J]. Strahlenther Onkol, 2014, 190(10): 872-881.
117. 葉欣, 范衛君, 王徽, 等. 熱消融治療原發性和轉移性肺部腫瘤專家共識 (2017年版) [J]. 中國肺癌雜志, 2017, 20(7): 433-445.
118. Shiina S, Tateishi R, Choi JI, et al. Asian conference on tumor ablation guidelines for hepatocellular carcinoma [J]. Liver Cancer, 2025, 14(5): 651-678.
119. Han S, Sung PS, Park SY, et al. Local ablation for hepatocellular carcinoma: 2024 expert consensus-based practical recommendation of the Korean Liver Cancer Association [J]. J Liver Cancer, 2024, 24(2): 131-144.
120. Páez-Carpio A, Gómez FM, Isus Olivé G, et al. Image-guided percutaneous ablation for the treatment of lung malignancies: current state of the art [J/OL]. Insights Imaging, 2021, 12(1): 57. doi: 10.1186/s13244-021-00997-5.
121. Zupanic A, Kos B, Miklavcic D. Treatment planning of electroporation-based medical interventions: electrochemotherapy, gene electrotransfer and irreversible electroporation [J]. Phys Med Biol, 2012, 57(17): 5425-5440.
122. Miller L, Leor J, Rubinsky B. Cancer cells ablation with irreversible electroporation [J]. Technol Cancer Res Treat, 2005, 4(6): 699-705.
123. Pistorius GA, Alexander C, Krisch CM, et al. Local platelet trapping as the cause of thrombocytopenia after hepatic cryotherapy [J]. World J Surg, 2005, 29(5): 657-660; discussion 661.
124. Yuan Z, Liu B, Hu C, et al. Clinical outcomes of percutaneous thermal ablation for pulmonary metastases from hepatocellular carcinoma: a retrospective study [J]. Int J Hyperthermia, 2020, 37(1): 651-659.
125. Hiraki T, Yamakado K, Ikeda O, et al. Percutaneous radiofrequency ablation for pulmonary metastases from hepatocellular carcinoma: results of a multicenter study in Japan [J]. J Vasc Interv Radiol, 2011, 22(6): 741-748.
126. Zhou Q, Li R, Wu S, et al. Metastasis-directed ablation of hepatocellular carcinoma with pulmonary oligometastases: a long-term multicenter study [J]. Radiol Med, 2025, 130(1): 25-36.
127. Zuo T, Lin W, Liu F, et al. Artificial pneumothorax improves radiofrequency ablation of pulmonary metastases of hepatocellular carcinoma close to mediastinum [J/OL]. BMC Cancer, 2021, 21(1): 505. doi: 10.1186/s12885-021-08223-7.
128. Chen J, Liu J, Zhang X, et al. Verteporfin-loaded hydrogel targeting YAP-mediated MDSCs recruitment for the treatment of residual tumors after incomplete radiofrequency ablation [J]. Theranostics, 2026, 16(5): 2372-2387.
129. Xiang Z, Bai M, Li G, et al. Safety and efficacy of ¹²⁵I brachytherapy for bilateral lung recurrences from hepatocellular carcinoma after resection or ablation [J]. J Cancer Res Clin Oncol, 2019, 145(7): 1907-1916.
130. Li C, Zhang F, Zhang W, et al. Feasibility of (125)I brachytherapy combined with sorafenib treatment in patients with multiple lung metastases after liver transplantation for hepatocellular carcinoma [J]. J Cancer Res Clin Oncol, 2010, 136(11): 1633-1640.
131. Yang C, He C, Yu S, et al. Effects of iodine-125 seed brachytherapy on patients with heterochronous pulmonary metastasis from hepatocellular carcinoma: a propensity score matching study [J]. J Cancer Res Ther, 2023, 19(4): 957-963.
132. Boas FE, Kemeny NE, Sofocleous CT, et al. Bronchial or pulmonary artery chemoembolization for unresectable and unablatable lung metastases: a phase Ⅰ clinical trial [J]. Radiology, 2021, 301(2): 474-484.
133. Kim S, Kim JH, Ko GY, et al. Bronchial artery embolization for hemoptysis caused by metastatic hepatocellular carcinoma [J/OL]. Sci Rep, 2022, 12(1): 6906. doi: 10.1038/s41598-022-10972-9.
134. Nezami N, Georgiades C, Hong KK, et al. Bronchial artery chemoembolization with radiopaque doxorubicin eluding beads in patients with malignant hemoptysis from metastatic lung cancer [J/OL]. Technol Cancer Res Treat, 2022, 21: 15330338221131167. doi: 10.1177/15330338221131167.
135. Fukutomi M, Yokota M, Chuman H, et al. Increased incidence of bone metastases in hepatocellular carcinoma [J]. Eur J Gastroenterol Hepatol, 2001, 13(9): 1083-1088.
136. Goodwin CR, Yanamadala V, Ruiz-Valls A, et al. A systematic review of metastatic hepatocellular carcinoma to the spine [J]. World Neurosurg, 2016, 91: 510-517. e514.
137. Hawkins JE, Dworzynski K, Haden N, et al. Spinal metastases and metastatic spinal cord compression: summary of updated NICE guidance [J/OL]. BMJ, 2023, 383: 1973. doi: 10.1136/bmj.p1973.
138. Tokuhashi Y, Matsuzaki H, Oda H, et al. A revised scoring system for preoperative evaluation of metastatic spine tumor prognosis [J]. Spine (Phila Pa 1976), 2005, 30(19): 2186-2191.
139. He J, Shi S, Ye L, et al. A randomized trial of conventional fraction versus hypofraction radiotherapy for bone metastases from hepatocellular carcinoma [J]. J Cancer, 2019, 10(17): 4031-4037.
140. Alcorn S, Cortés áA, Bradfield L, et al. External beam radiation therapy for palliation of symptomatic bone metastases: an ASTRO Clinical Practice Guideline [J]. Pract Radiat Oncol, 2024, 14(5): 377-397.
141. National Institute for Health and Care Excellence. Spinal metastases and metastatic spinal cord compression: NICE guideline NG234 [M/OL]. London: National Institute for Health and Care Excellence, 2023, (2023-09-06) [2026-09-01] https://www.nice.org.uk/guidance/ng234.
142. Golimbu C, Firooznia H, Rafii M. Hepatocellular carcinoma with skeletal metastasis [J]. Radiology, 1985, 154(3): 617-618.
143. He J, Zeng ZC, Tang ZY, et al. Clinical features and prognostic factors in patients with bone metastases from hepatocellular carcinoma receiving external beam radiotherapy [J]. Cancer, 2009, 115(12): 2710-2720.
144. Jung IH, Yoon SM, Kwak J, et al. High-dose radiotherapy is associated with better local control of bone metastasis from hepatocellular carcinoma [J]. Oncotarget, 2017, 8(9): 15182-15192.
145. Choi C, Seong J. Predictive factors of palliative radiotherapy response and survival in patients with spinal metastases from hepatocellular carcinoma [J]. Gut Liver, 2015, 9(1): 94-102.
146. Guninski RS, Cuccia F, Alongi F, et al. Efficacy and safety of SBRT for spine metastases: a systematic review and meta-analysis for preparation of an ESTRO practice guideline [J/OL]. Radiother Oncol, 2024, 190: 109969. doi: 10.1016/j.radonc.2023.109969.
147. Bindels BJJ, Mercier C, Gal R, et al. Stereotactic body and conventional radiotherapy for painful bone metastases: a systematic review and meta-analysis [J/OL]. JAMA Netw Open, 2024, 7(2): e2355409. doi: 10.1001/jamanetworkopen.2023.55409.
148. Lee E, Kim TG, Park HC, et al. Clinical outcomes of stereotactic body radiotherapy for spinal metastases from hepatocellular carcinoma [J]. Radiat Oncol J, 2015, 33(3): 217-225.
149. Yoo GS, Park HC, Yu JI, et al. Stereotactic ablative body radiotherapy for spinal metastasis from hepatocellular carcinoma: its oncologic outcomes and risk of vertebral compression fracture [J]. Oncotarget, 2017, 8(42): 72860-72871.
150. Seong J, Koom WS, Park HC. Radiotherapy for painful bone metastases from hepatocellular carcinoma [J]. Liver Int, 2005, 25(2): 261-265.
151. Bauer H, Tomita K, Kawahara N, et al. Surgical strategy for spinal metastases [J]. Spine (Phila Pa 1976), 2002, 27(10): 1124-1126.
152. Fisher CG, DiPaola CP, Ryken TC, et al. A novel classification system for spinal instability in neoplastic disease: an evidence-based approach and expert consensus from the Spine Oncology Study Group [J]. Spine (Phila Pa 1976), 2010, 35(22): E1221-E1229.
153. Tokuhashi Y, Matsuzaki H, Toriyama S, et al. Scoring system for the preoperative evaluation of metastatic spine tumor prognosis [J]. Spine (Phila Pa 1976), 1990, 15(11): 1110-1113.
154. Bilsky MH, Laufer I, Fourney DR, et al. Reliability analysis of the epidural spinal cord co: mpression scale [J]. J Neurosurg Spine, 2010, 13(3): 324-328.
155. Mirels H. Metastatic disease in long bones. A proposed scoring system for diagnosing impending pathologic fractures [J]. Clin Orthop Relat Res, 1989(249): 256-264.
156. Van der Linden YM, Dijkstra PDS, Kroon HM, et al. Comparative analysis of risk factors for pathological fracture with femoral metastases [J]. J Bone Joint Surg Br, 2004, 86(4): 566-573.
157. Gonzalez MR, Bryce-Alberti M, Pretell-Mazzini J. Management of long bones metastatic disease: concepts that we all know but not always remember [J]. Orthop Res Rev, 2022, 14: 393-406.
158. Baba K, Kaida H, Hattori C, et al. Tumoricidal effect and pain relief after concurrent therapy by strontium-89 chloride and zoledronic acid for bone metastases [J]. Hell J Nucl Med, 2018, 21(1): 15-23.
159. 付欽卿, 袁欽詩, 楊夏欣. 放射性核素氯化鍶 (⁸⁹Sr) 聯合唑來膦酸對原發性肝癌骨轉移的療效及安全性 [J]. 肝臟, 2025, 30(2): 222-225.
160. Naruto K, Kawaoka T, Yamasaki S, et al. Clinical outcomes of switching from zoledronic acid to denosumab for the management of severe bone metastasis from hepatocellular carcinoma: a single-center, open-label, prospective intervention trial [J]. Yonago Acta Med, 2023, 66(4): 422-431.
161. Stopeck AT, Lipton A, Body JJ, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study [J]. J Clin Oncol, 2010, 28(35): 5132-5139.
162. Dodd GD, Baron RL, Oliver JH, et al. Enlarged abdominal lymph nodes in end-stage cirrhosis: CT-histopathologic correlation in 507 patients [J]. Radiology, 1997, 203(1): 127-130.
163. Yang A, Xiao W, Ju W, et al. Prevalence and clinical significance of regional lymphadenectomy in patients with hepatocellular carcinoma [J]. ANZ J Surg, 2019, 89(4): 393-398.
164. Spoletini G, Mauro A, Caimano M, et al. The role of lymphadenectomy in the surgical treatment of hepatocellular carcinoma: a systematic review and meta-analysis [J/OL]. Cancers (Basel), 2024, 16(24): 4166. doi: 10.3390/cancers16244166.
165. Wang Y, Li Q, Zhang L, et al. Efficacy and dose-response relationship of stereotactic body radiotherapy for abdominal lymph node metastases from hepatocellular carcinoma [J]. Oncologist, 2023, 28(6): e369-e378.
166. Matoba M, Tsuchiya H, Kondo T, et al. Stereotactic body radiotherapy delivered with IMRT for oligometastatic regional lymph node metastases in hepatocellular carcinoma: a single-institutional study [J]. J Radiat Res, 2020, 61(5): 776-783.
167. Utsumi M, Matsuda H, Sadamori H, et al. Resection of metachronous lymph node metastases from hepatocellular carcinoma after hepatectomy: report of four cases [J]. Acta Med Okayama, 2012, 66(2): 177-182.
168. Yuan Z, Xing A, Zheng J, et al. Safety and technical feasibility of percutaneous ablation for lymph node metastases of hepatocellular carcinoma [J]. Int J Hyperthermia, 2019, 36(1): 160-168.
169. Gao F, Gu Y, Huang J, et al. Radiofrequency ablation of retroperitoneal metastatic lymph nodes from hepatocellular carcinoma [J]. Acad Radiol, 2012, 19(8): 1035-1040.
170. Parvinian A, Schmitz JJ, Welch BT, et al. A single-institution experience in percutaneous image-guided cryoablation of lymph node metastases [J]. AJR Am J Roentgenol, 2021, 217(1): 152-156.
171. Filippiadis DK, Pua U, Georgiadi E, et al. Percutaneous ablation of metastatic lymph nodes: an insight from the comparison of efficacy and safety between cryoablation and radiofrequency ablation [J]. Cardiovasc Intervent Radiol, 2022, 45(8): 1134-1140.
172. Huang D, Zhong Z, Zhang F, et al. Clinical outcomes and individualized seed implantation planning for iodine-125 seeds brachytherapy in lymph node metastases [J]. J Cancer, 2026, 17(3): 507-514.
173. Momoi H, Shimahara Y, Terajima H, et al. Management of adrenal metastasis from hepatocellular carcinoma [J]. Surg Today, 2002, 32(12): 1035-1041.
174. Xu B, Zhao X, Chen D, et al. Two-institution results of stereotactic body radiation therapy (SBRT) for treating adrenal gland metastases from liver cancer [J/OL]. BMC Cancer, 2023, 23(1): 73. doi: 10.1186/s12885-023-10519-9.
175. Ehret F, Kaul D, Kufeld M, et al. Robotic stereotactic body radiotherapy for the management of adrenal gland metastases: a bi-institutional analysis [J]. J Cancer Res Clin Oncol, 2023, 149(3): 1095-1101.
176. Umakoshi N, Matsui Y, Tomita K, et al. Image-guided ablation therapies for extrahepatic metastases from hepatocellular carcinoma: a review [J/OL]. Cancers (Basel), 2023, 15(14): 3665. doi: 10.3390/cancers15143665.
177. Lyu N, Kong Y, Pan T, et al. Survival benefits of computed tomography-guided thermal ablation for adrenal metastases from hepatocellular carcinoma [J]. Int J Hyperthermia, 2019, 36(1): 1003-1011.
178. Zhou K, Pan J, Yang N, et al. Effectiveness and safety of CT-guided percutaneous radiofrequency ablation of adrenal metastases [J/OL]. Br J Radiol, 2018, 91(1085): 20170607. doi: 10.1259/bjr.20170607.
179. Pusceddu C, Faiella E, Cau C, et al. Computed tomography-guided cryoablation in treating adrenal metastases: a retrospective single-center study [J]. Diagn Interv Radiol, 2025, 31(4): 372-376.
180. Aoun HD, Littrup PJ, Nahab B, et al. Percutaneous cryoablation of adrenal metastases: technical feasibility and safety [J]. Abdom Radiol (NY), 2021, 46(6): 2805-2813.
181. Park BK, Fujimori M, Shen SH, et al. Asian Conference on Tumor Ablation Guidelines for Adrenal Tumor Ablation [J]. Endocrinol Metab (Seoul), 2021, 36(3): 553-563.
182. Welch BT, Atwell TD, Nichols DA, et al. Percutaneous image-guided adrenal cryoablation: procedural considerations and technical success [J]. Radiology, 2011, 258(1): 301-307.
183. Hou Y, Liu R, Cui Y, et al. Short-term effectiveness and safety of CT-guided radioactive iodine-125 seed implantation for treatment of adrenal metastases [J]. J Contemp Brachytherapy, 2022, 14(2): 148-156.
184. Yan G, Zhang K, Yan L, et al. Long-term survival outcomes following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal metastasis of hepatocellular carcinoma patients [J/OL]. World J Surg Oncol, 2024, 22(1): 144. doi: 10.1186/s12957-024-03426-1.
185. Xia F, Ndhlovu E, Zhang M, et al. Ruptured hepatocellular carcinoma: current status of Research [J/OL]. Front Oncol, 2022, 12: 848903. doi: 10.3389/fonc.2022.848903.
186. Healy JC. Detection of peritoneal metastases [J]. Cancer Imaging, 2001, 1(2): 4-12.
187. Spiliotis J, Nikolaou G, Kopanakis N, et al. Hepatocellular carcinoma peritoneal metastasis: role of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) [J]. Gulf J Oncolog, 2017, 1(24): 20-23.
188. Tabrizian P, Franssen B, Jibara G, et al. Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy in patients with peritoneal hepatocellular carcinoma [J]. J Surg Oncol, 2014, 110(7): 786-790.
189. Okuda T, Hayashi N, Takahashi M, et al. Clinical outcomes of brain metastases from hepatocellular carcinoma: a multicenter retrospective study and a literature review [J]. Int J Clin Oncol, 2018, 23(6): 1095-1100.
190. Choi HJ, Cho BC, Sohn JH, et al. Brain metastases from hepatocellular carcinoma: prognostic factors and outcome: brain metastasis from HCC [J]. J Neurooncol, 2009, 91(3): 307-313.
191. Park ES, Kwon DH, Park JB, et al. Gamma knife surgery for treating brain metastases arising from hepatocellular carcinomas [J]. J Neurosurg, 2014, 121 Suppl: 102-109.
192. Mustafayev K, Mustafayev FNA, Ganiyani MA, et al. Treatment modalities and survival outcomes in patients with hepatocellular carcinoma with brain metastases (HCC-BM): a large national study [J]. J Clin Oncol, 2025, 43(16_suppl): e14007. doi: 10.1200/JCO.2025.43.16_suppl.e14007.
193. Schiff D, Messersmith H, Brastianos PK, et al. Radiation therapy for brain metastases: ASCO guideline endorsement of ASTRO guideline [J]. J Clin Oncol, 2022, 40(20): 2271-2276.
194. Cook AM, Morgan Jones G, Hawryluk GWJ, et al. Guidelines for the acute treatment of cerebral edema in neurocritical care patients [J]. Neurocrit Care, 2020, 32(3): 647-666.
195. Le Rhun E, Guckenberger M, Smits M, et al. EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours [J]. Ann Oncol, 2021, 32(11): 1332-1347.
196. Ye K, Fan Q, Yuan M, et al. Prognostic value of postoperative circulating tumor DNA in patients with early- and intermediate-stage hepatocellular carcinoma [J/OL]. Front Oncol, 2022, 12: 834992. doi: 10.3389/fonc.2022.834992.
197. Ren Q, Li S, Zhong G, et al. Non-invasive tumor-na?ve minimal residual disease detection of liver cancer by incorporating circulating tumor DNA features and alpha-fetoprotein: a prospective study [J/OL]. Cancer Med, 2024, 13(24): e70511. doi: 10.1002/cam4.70511.
198. Ji GW, Zhu FP, Xu Q, et al. Radiomic features at contrast-enhanced CT predict recurrence in early stage hepatocellular carcinoma: a multi-institutional study [J]. Radiology, 2020, 294(3): 568-579.
199. Hou S, Hu S, Wu Q, et al. Efficacy and safety of stereotactic body radiation therapy combined with targeted agents and immunotherapies in hepatocellular carcinoma: a systematic review and meta-analysis [J/OL]. BMC Cancer, 2025, 25(1): 1602. doi: 10.1186/s12885-025-15061-4.
200. Shi D, Shi Y, Kaseb AO, et al. Chimeric antigen receptor-glypican-3 t-cell therapy for advanced hepatocellular carcinoma: results of phase Ⅰ trials [J]. Clin Cancer Res, 2020, 26(15): 3979-3989.
201. Fu Y, Urban DJ, Nani RR, et al. Glypican-3-specific antibody drug conjugates targeting hepatocellular carcinoma [J]. Hepatology, 2019, 70(2): 563-576.
202. Heo J, Reid T, Ruo L, et al. Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer [J]. Nat Med, 2013, 19(3): 329-336.
203. Shen X, Zhao D, Wang F, et al. Dietary intervention reshapes gut microbiota and lipid metabolism to enhance anti-tumor immunity and prognosis in hepatocellular carcinoma: a randomized controlled trial [J/OL]. BMC Cancer, 2026, 26(1): 42. doi: 10.1186/s12885-025-15325-z.

Next Article
Interpretation of the 2026 ACC/AHA Multisociety Guideline on the Management of Dyslipidemia

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Chinese Expert Consensus on the Multidisciplinary Diagnosis and Management of Hepatocellular Carcinoma with Extrahepatic Metastases（2026 Edition）

Abstract Full text Figures/Tables Video References Cited by

Next Article

Format

Content